tetano
Editor, Senior Moderator
Antivir Ther
. 2020 Jun 4.
doi: 10.3851/IMP3362. Online ahead of print.
Combination Antiviral Therapy With Lopinavir/Ritonavir, Arbidol and interferon-α1b for COVID-19
Xiangyang Xie[SUP] 1 [/SUP], Yuanliang Jiang[SUP] 2 [/SUP], Yuan Zeng[SUP] 1 [/SUP], Hui Liu[SUP] 1 [/SUP]
Affiliations
Abstract
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.
. 2020 Jun 4.
doi: 10.3851/IMP3362. Online ahead of print.
Combination Antiviral Therapy With Lopinavir/Ritonavir, Arbidol and interferon-α1b for COVID-19
Xiangyang Xie[SUP] 1 [/SUP], Yuanliang Jiang[SUP] 2 [/SUP], Yuan Zeng[SUP] 1 [/SUP], Hui Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 32496210
- DOI: 10.3851/IMP3362
Abstract
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.